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Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a malignant primary liver 
carcinoma characterized by the unequivocal presence of both hepatocytic and cholangiocytic 
differentiation within the same tumor. Recent research has highlighted that cHCC-CCAs are 
more heterogeneous than previously expected. In the updated consensus terminology and 
WHO 2019 classification, “classical type” and “subtypes with stem-cell features” of the WHO 
2010 classification are no longer recommended. Instead, it is recommended that the presence 
and percentages of various histopathologic components and stem-cell features be mentioned 
in the pathologic report. The new terminology and classification enable the exchange of 
clearer and more objective information about cHCC-CCAs, facilitating multi-center and multi-
national research. However, there are limitations to the diagnosis of cHCC-CCA by imaging 
and biopsy. cHCC-CCAs showing typical imaging findings of HCC could be misdiagnosed as 
HCC and subjected to inappropriate treatment, if other clinical findings are not sufficiently 
considered. cHCC-CCAs showing at least one of the CCA-like imaging features or unusual 
clinical features should be subjected to biopsy. There may be a sampling error for the biopsy 
diagnosis of cHCC-CCA. An optimized diagnostic algorithm integrating clinical, radiological, 
and histopathologic information of biopsy is required to resolve these diagnostic pitfalls. 
(J Liver Cancer 2021;21:12-24)
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CCA) is a primary liver cancer (PLC) showing both hepato-
cytic and cholangiocytic differentiation, it reportedly ac-
c o u n t s  f o r  a b o u t  1 - 5 %  o f  a l l  P L C s . 1 - 3 G i v e n  t h e 
heterogeneous histopathologic nature of cHCC-CCAs, im-
aging or biopsy diagnosis is challenging, and the ideal diag-
nostic strategy for cHCC-CCAs in non-surgical candidates is 
not sufficiently well defined. Despite several recent investiga-
tions, the pathogenesis, histopathology, and genetics of this 
enigmatic tumor have not been fully understood. Reflecting 
on the current understanding, the consensus terminology of 
cHCC-CCA was published in 2018, and the WHO classifica-
tion of cHCC-CCA was revised in 2019.1,4 Herein, we aimed 
to comprehensively review the updated information on the 
pathologic and radiologic diagnosis of cHCC-CCAs.
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The 2018 UpDaTeD CONseNsUs TeRmI-
NOlOgy aND WhO 2019 ClassIfICaTION
In the updated 2018 consensus terminology and WHO 
2019 classification,1,4 cHCC-CCA is defined as a PLC with 
the unequivocal presence of both hepatocytic and cholangio-
cytic differentiation within the same tumor, similar to WHO 
2010 classification. cHCC-CCA is characterized by complex 
morphological and immunophenotypical features and can be 
diagnosed regardless of the percentage of each component if 
the components are present unequivocally. However, multi-
focal HCC or CCA, collision of HCC and CCA arising sepa-
rately, any form of hepatoblastoma or variants, pediatric 
transitional liver cell tumor or variants, and HCC or CCA 
with neuroendocrine components should not be classified as 
cHCC-CCAs.
In the WHO 2010 classification, cHCC-CCAs were cate-
gorized as “classical type” and three subtypes with stem-cell 
features, including “typical subtype,” “intermediate-cell sub-
type,” and “cholangiolocellular subtype”.5 However, criti-
cisms have been raised about the stem cell subtypes. Tumor 
cells with stem/progenitor cell features can be observed in 
most cHCC-CCAs, including the classical type. Besides, 
some PLCs can display two or more histologic components 
and often do not match the specific subtype of the WHO 
2010 classification.6,7 Therefore, in the updated WHO 2019 
classification, the use of “cHCC-CCA with stem-cell feature” 
is no longer recommended.8 It is recommended that the 
presence and percentages of various histopathologic compo-
nents and stem-cell features be mentioned in the pathologic 
report.
Cholangiolocarcinoma (CLC) comprises tumor cells re-
sembling cholangioles (canals of Hering), where the hepatic 
stem/progenitor cells are located.9,10 CLC also shows enriched 
CCA-like features and the absence of HCC-like features in 
the molecular profile, which is distinct from the phenotypes 
of other stem-cell subtypes of cHCC-CCA.11 However, re-
cent morphometric and immunohistochemical (IHC) analy-
ses revealed that the CLC originated not from the cholangi-
ole but the interlobular bile duct.12 In the updated WHO 
2019 classification, the CLC is classified as cHCC-CCA only 
when it is mixed with HCC or intermediate carcinoma. 
However, if the CLC component exists alone or is mixed 
with CCA only, it is classified as CCA, not cHCC-CCA. 
Intermediate cell carcinoma is composed of tumor cells 
showing intermediate features between hepatocytes and 
cholangiocytes at the cellular level, and it displays both hepa-
tocytic and cholangiocytic IHC markers. PLCs comprising 
only intermediate cells are diagnosed as intermediate cell 
carcinoma, and those showing mixed intermediate cell carci-
noma and other types of tumors (HCC, CCA, or CLC) are 
classified as cHCC-CCAs. Further studies are needed to clar-
ify whether intermediate cell carcinoma is a distinct clinico-
pathological entity rather than a histopathological spectrum. 
The diagnosis of cHCC-CCA should be based on the his-
tomorphology on hematoxylin-eosin stain. There are occa-
sions when it is not easy to assess the HCC or CCA area 
based on histomorphology, especially when the tumor is 
poorly differentiated, and in such case, immunohistochemis-
try can be useful to confirm hepatocytic and/or cholangio-
cytic differentiation. However, the expression of IHC mark-
ers alone, without the corresponding histomorphologic 
features, is not adequate for diagnosis. IHC markers for he-
patocytic differentiation include HepPar-1 (75-85% positivi-
ty), Arginase-1 (85-95% positivity), polyclonal carcinoem-
bryonic antigen (CEA) with canalicular expression (50-80% 
positivity), CD10 with canalicular expression (50-75% posi-
tivity), and alpha-fetoprotein (AFP) (30% positivity), among 
others; IHC markers for cholangiocytic differentiation in-
clude K7 (>90% positivity), K19 (>75% positivity) and Ep-
CAM (>90% positivity), among others. A wide variety of 
IHC markers, including K19, EpCAM, CD56, KIT, and 
CD133, have been used to confirm the stem/progenitor cell 
phenotype. Some of these markers, including K19, EpCAM, 
and CD56, can also be expressed in cholangiocytes at various 
development stages. Therefore, it is important that these an-
tibodies be used and interpreted by an experienced patholo-
gist, taking into account the tumor histomorphology.
paThOgeNesIs Of chCC-CCa
The pathogenesis of cHCC-CCA remains elusive. Two 
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possibilities have been postulated regarding the pathogenesis 
of cHCC-CCA: 1) trans-differentiation of HCC or CCA into 
the other component, and 2) derivation of cHCC-CCA from 
the hepatic stem/progenitor cell.13 cHCC-CCAs often show 
tumor cell components with stem-cell features, and thus, liv-
er stem/progenitor cells have been proposed as a potential 
origin of cHCC-CCAs.14 Recently, increasing clinical and ex-
perimental evidence indicated that cHCC-CCA could result 
from plasticity or the dedifferentiation of PLC. In a mouse 
model, PLCs from the same cell of origin were suggested to 
show various hepatocytic/cholangiocytic differentiation and 
stem-cell features,15 and advanced HCC was reported to 
show molecular and pathologic features of CCA.16 Among 
PLCs treated with trans-arterial chemoembolization, the oc-
currence of cHCC-CCA was reported, suggesting the poten-
tial microenvironmental regulation of tumor trans-differen-
tiation.17
mOleCUlaR feaTURes Of chCC-CCa
Despite recent active investigations since early 2000, the 
genetic and molecular features of cHCC-CCA remain un-
clear. The recently reported molecular features of cHCC-
CCAs are summarized in Table 1; these are significantly het-
erogenous. It should be noted that these studies were 
performed on a limited series, reflecting the low frequency of 
this tumor. A genetic study of each microdissected compo-
nent of cHCC-CCA revealed that HCC and CCA compo-





Fujii et al.18 
(2000) 
Loss of heterozygosity 8 HCC and CCA in cHCC-CCA shared allelic losses, suggesting clonality.
Cazals-Hatem 
et al.21 (2004) 
Loss of heterozygosity, 
Sanger sequencing
15 Mutation patterns, allelic losses were closer to CCA.
Coulouarn et 
al.14 (2012) 
Gene expression array 20 Stem/progenitor feature, down-regulation of hepatocyte differentiation related 
genes, up-regulation biliary differentiation related genes.
TGF-β and Wnt/β-catenin signaling activation were the major pathways of cHCC-
CCA.




7 Mutation patterns and allelic losses of cHCC-CCA with chronic hepatitis were close 
to HCC. Those without chronic hepatitis were diverse.
Moeini et al.11 
(2017) 





18 CLC showed enriched TGF-β signaling and biliary-like feature compared to other 
types of cHCC-CCAs. 
cHCC-CCA with stem cell features often showed SALL4 expression, progenitor-like 
signature and poor prognostic signature.
Classical type tumors showed biphenotypic profile, and shared copy number 
variants, suggesting clonality.
Sasaki et al.7 
(2015) 
Sanger sequencing 53 cHCC-CCA exhibited diverse mutations, which might reflect the etiological and 
histological subtypes, and tumor aggressiveness.




15 HCC and CCA in cHCC-CCA showed both of synonymous and non-synonymous 
genetic alterations, suggesting clonality and intra-tumoral genetic heterogeneity.
cHCC-CCA showed expression of stem/progenitor markers.





10 Mutation and transcription patterns were closer to HCC.




20 Mutation patterns were close to HCC.
HCC, hepatocellular carcinoma; CCA, cholangiocarcinoma; cHCC-CCA, combined hepatocellular-cholangiocarcinoma; TGF-β, transforming 
growth factor-beta; CLC, Cholangiolocellular carcinoma; SALL4, Sal-like protein 4.
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CT or MRI 29 - 41-48% homogeneous 
or heterogeneous 
arterial enhancement 
- 33-41% washout 
- 22-26% capsular 
appearance
- 52-59% peripheral arterial 
enhancement  
- 48-74% delayed central 
enhancement
- 42-45% liver surface retraction 
- 17-35% bile duct dilatation 
- Preoperative diagnosis of cHCC-





MRI 11 - 45% diffuse 
heterogeneous arterial 
enhancement 
- 27% washout 
- 9% capsular appearance
- 55% peripheral arterial 
enhancement and progressive 
enhancement
- 5% bile duct dilatation 
- 27% tumor in vein 
- Moderately high signal on T2, 
progressive enhancement, and 




MRI 20 - Strong (85%) or weak (15%) 
peripheral arterial enhancement 
- Target appearance in 20 min 
hepatobiliary phase (50%).
- Irregular (60%), lobulating (30%), 
or globular (10%) shape. 
- Irregular shape, strong peripheral 
enhancement, and absence 
of hepatobiliary phase target 
appearance are more commonly 
seen in cHCC-CCA than CCA
Wells et al.38 
(2015)
CT or MRI 29 - 7% diffuse arterial 
enhancement and 
washout 
- 10% capsular 
appearance
- 79% peripheral arterial 
enhancement and washout or 
fade in portal phase 
- 7% peripheral enhancement in 
both of arterial and portal phases
- 43% heterogeneous appearance 
- 26% liver surface retraction 
- 3% fat in mass 
- 9% tumor in vein 
- 9% bile duct dilatation
Potretzke et 
al.45 (2016)
CT or MRI 61 - 25% arterial 
enhancement and 
washout 
- 8% arterial 
enhancement and 
capsular appearance 
- 21% arterial 
enhancement, 
washout, and capsular 
appearance
- 59% peripheral arterial 
enhancement 
- 16% peripheral washout 
- 54% progressive central 
enhancement 
- 20% marked diffusion restriction
- 26% liver surface retraction 
- 8% bile duct dilatation 
- With major features only, 54% 
cHCC-CCAs met the criteria of 
HCC. 
- 88% of HCC mimickers showed 
at least one of ancillary features 
favoring non-HCC malignancy 
over HCC.
Park et al.24 
(2017)
MRI 82 - 59% global arterial 
enhancement 
- 31% washout 
- 15% capsular 
appearance
- 39% peripheral or rim arterial 
enhancement 
- 37% targetoid appearance in 
hepatobiliary phase
- Irregular (21%), lobulating (54%), 
or round (26%) margin 
- 15% intralesional fat 
- 12% bile duct dilatation 
- 12% tumor in vein 
- The hypervascular cHCC-CCAs 
were associated with a larger 
HCC component, smaller CCA 




MRI 33 - 49% non-rim arterial 
enhancement 
- 39% washout
- 42% rim arterial enhancement - 13% liver surface retraction 
- 6% intralesional fat 
- 12% intralesional blood product 
- 15% bile duct dilatation 
- 9% tumor in vein
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nents shared genetic and chromosomal aberrations in most 
cases, suggesting a single clonal origin.11,18-20 Several studies 
have reported that the mutation profile of cHCC-CCA is 
similar to that of CCA.21 In contrast, more recent studies 
have reported that the mutation profile is rather similar to 
that of HCC.20,22,23 Moeini et al.11 studied gene expression via 
unsupervised clustering and reported the molecular features 
of classical, stem cell, and CLC types. Concerning the back-
ground liver, the genome-wide substitution patterns of 
cHCC-CCAs with chronic hepatitis overlapped with HCCs, 
whereas those of hepatitis-negative cHCC-CCAs were di-
verse.22 These findings suggest that the genetic characteristics 
of cHCC-CCAs are heterogeneous, similar to their histo-
pathologic features. 
ClINICal CONsIDeRaTIONs IN The DIag-
NOsIs Of chCC-CCa
As with HCCs, cHCC-CCAs show male predominance. In 
cHCC-CCA, the incidence of chronic hepatitis and cirrhosis 
is 23-38% and 50-62%, respectively; these ratios are similar 
to those of HCC,24-27 or intermediate between those of HCC 
and CCA.24-31 Previously, a low incidence of chronic hepati-
tis/cirrhosis was reported in western series;32 however, in re-
cently reported country-wide data from the United States, 
the incidence of chronic hepatitis/cirrhosis is similar to that 
in HCC. The etiologies of chronic hepatitis/cirrhosis include 
hepatitis B (27-80%), hepatitis C (4-38%), or alcoholic liver 
disease (6-36%).24-31 The chronic hepatitis and cirrhosis are 
risk factors not only for HCCs but also for CCAs.33 However, 
the association of cHCC-CCAs with other risk factors for 
CCAs, including parasitic fluke, primary sclerosing cholangi-
tis, and choledocholithiasis, remains unknown.
Serologic markers, including AFP, CEA, and carbohydrate 
antigen 19-9 (CA19-9), are often evaluated when a PLC is 
suspected. In cHCC-CCA, serum AFP was reported to be 
similar to that in HCC and higher than that in CCA in most 
reports;29-32,34,35 however, in some reports, the lower AFP lev-
els were reported to be similar to that in CCAs.36 Varying 





LR-M features Other features
Major features
Jeon et al.48 
(2019)
MRI 70 - 73% arterial 
enhancement 
- 61% washout 
- 20% enhancing capsular 
appearance
- 43% peripheral arterial 
enhancement 
- 10% peripheral washout 
- 33% delayed central 
enhancement 
- 14% targetoid appearance in 
transitional phase 
- 37% targetoid appearance in 
hepatobiliary phase 
- 10% targetoid diffusion restriction
- 10% intralesional fat 
- Approximately 61% and 37% 
cHCC-CCAs were categorized as 
LR-M and LR-5/4, respectively.
Kim et al.47 
(2020)
MRI 43 - 40% non-rim arterial 
enhancement 
- 67% washout 
- 28% enhancing capsular 
appearance
- 58% peripheral arterial enhance-
ment 
- 9% peripheral washout 
- 51% delayed central enhance-
ment 
- 14% targetoid appearance in tran-
sitional phase 
- 42% targetoid appearance in 
hepatobiliary phase 
- 7% infiltrative appearance
- 14% liver surface retraction 
- 2% intralesional fat 
- 7% intralesional blood product 
- 5% bile duct dilatation
cHCC-CCA, combined hepatocellular-cholangiocarcinoma; CCA, cholangiocarcinoma; HCC, hepatocellular carcinoma; CT, computed tomography; 
MRI, magnetic resonance imaging; LR-M, Liver Imaging Reporting and Data System M.
Table 2. continued
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these were not significantly higher than those in HCCs.27,36,37 
The serum CEA level in cHCC-CCA was not significantly 
different from that in HCC.27,29,32 Discordant serologic tumor 
marker levels and imaging findings may be a clue to the diag-
nosis of cHCC-CCA.38
RaDIOlOgIC DIagNOsIs Of chCC-CCa
The primary goal of imaging diagnosis of PLC is to distin-
guish HCC from other PLCs, including cHCC-CCA and 
CCA. In high-risk individuals for HCC, typical imaging find-
ings of HCC (arterial enhancement and washout, or LR-5 of 
Liver Imaging and Reporting and Data System [LI-RADS]) 
show very high positive predictive value for HCC; therefore, 
most HCC management guidelines allow imaging diagnosis 
of HCC without biopsy in those patients.39,40 The definition 
of high-risk individuals is similar across guidelines with mi-
nor differences. Individuals with chronic hepatitis B or cir-
rhosis of any cause are included in the high-risk category ac-
cording to most guidelines.39 Most patients with cHCC-CCA 
can also be included in the high-risk category, as the inci-
dence of chronic hepatitis and cirrhosis in such patients is 
similar or slightly lower than that in patients with HCC. 
When PLC is suspected in patients who are not at high risk 
for HCC, the lesion should be subjected to biopsy, and not 
imaging diagnosis alone. LI-RADS is an imaging diagnostic 
algorithm for HCC, integrated into the American Associa-
tion for the Study of Liver Diseases (AASLD) guideline.40,41 
We can categorize the observations into the following LI-
RADS categories: LR-1 (definitely benign), LR-2 (probably 
benign), LR-3 (intermediate probability of malignancy), 
LR-4 (probably HCC), LR-5 (definitely HCC), and LR-M 
(probably or definitely malignant, not necessarily HCC). 
When a hepatic lesion is categorized as LR-5, it can be diag-
Figure 1. A 57-year-old male with combined hepatocellular-cholangiocarcinoma (chcc-ccA) in the background liver of hepatitis b-virus and 
alcohol related chronic hepatitis. A 3.4-cm infiltrative mass lesion in the liver segment 7 shows low-signal intensity in precontrast T1-weighted 
image (A), peripheral enhancement in the arterial phase (b), absence of washout in portal phase (c) and 2-minute delay phase (d), decreased 
hepatobiliary uptake in hepatobiliary phase (e), and high-signal intensity in T2-weighted image (f) of gadoxetate-enhanced magnetic resonance 
imaging. it is categorized as liver imaging Reporting and data System M based on targetoid appearance. On pathologic examination (g-i), the 
tumor shows cholangiocarcinoma (ccA) component in whitish and fibrotic area of gross specimen and hepatocellular carcinoma (hcc) 
component in more yellowish area of resected specimen, and there are transitional differentiation zones between them (g, gross feature of 
resected specimen; h, scanning view of hematoxylin-eosin stain; i, map of histological components). hcc and ccA areas are not distinguishable 
in magnetic resonance imaging.
A
g h i
b c d e f
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nosed as HCC without a biopsy. When the lesion is catego-
rized as LR-M, a biopsy is recommended for confirmative 
diagnosis. The computed tomography (CT) and magnetic 
resonance imaging (MRI) findings of the recently reported 
cHCC-CCA are summarized in Table 2. The radiologic ap-
pearance of cHCC-CCA can resemble either HCC or CCA; 
therefore, cHCC-CCA is often misdiagnosed as HCC or 
CCA.42 The arterial enhancement pattern on CT or MRI is 
one of the most critical imaging features that distinguishes 
HCC from other PLCs. HCCs often show non-peripheral 
enhancement in the arterial phase, whereas CCAs often show 
peripheral (rim-like) enhancement. For cHCC-CCA, the 
most common arterial phase enhancement pattern is a pe-
ripheral enhancement, seen in approximately 39-100% of 
cHCC-CCAs (Fig. 1, 2).38,42-48 However, approximately 40-
59% of cHCC-CCAs exhibit a non-peripheral enhancement 
pattern in the arterial phase.24,42,43,45,47 The washout and cap-
sular appearance are major features that, in conjunction with 
non-peripheral enhancement, are suggestive of HCC; they 
are reported to be observed in 27-67% and 9-28% of cHCC-
CCAs, respectively (Fig. 3).24,38,42,43,45,47,48
Although a considerable number of cHCC-CCAs show 
major features suggesting HCC, the ancillary features sug-
gesting a non-HCC malignancy should also be taken into ac-
Figure 2. A 58-year-old male showing combined hepatocellular-cholangiocarcinoma (chcc-ccA) with cholangiolocellular (clc) and 
intermediate-cell carcinoma components, developed in cirrhosis of unknown etiology. A 3.2-cm lobulated mass lesion in the liver segment 4 
shows low-signal intensity in precontrast T1-weighted image (A), peripheral enhancement in the arterial phase (b), absence of washout in portal 
phase (c) and delayed central enhancement in hepatobiliary phase (d) of gadoxetate-enhanced magnetic resonance imaging (MRi). The lesion 
also shows nodule-in-nodule appearance: the inner nodule exhibited hypervascularity in arterial phase, absence of washout in portal phase, and 
low-signal intensity in T2-weighted image (e). As the lesion shows peripheral arterial enhancement and delayed central enhancement, it is 
categorized as liver imaging Reporting and data System M. On pathologic examination (f-l), the tumor shows complex mixture of hepatocellular 
carcinoma (hcc) (i), intermediate-cell carcinoma (J), clc (k), and cholangiocarcinoma (ccA) (l) components. On MRi, the ccA component, 
corresponding the inner nodule, was more hypervascular than other components including hcc ([f] gross feature of resected specimen; 
[g] scanning view of hematoxylin-eosin [h-e] stain; [h] map of histological components; [i-l] h-e stain, original magnification, ×100).
A b c d e
f
i J k l
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count to reduce misdiagnosis. These ancillary features, called 
LR-M features, include targetoid appearance (peripheral ar-
terial enhancement, peripheral washout, and delayed central 
enhancement), marked diffusion restriction, and infiltrative 
appearance. Potretzke et al.45 reported that 54% (33/61) of 
cHCC-CCAs showed major features typical of HCC, but 
88% (29/33) of them demonstrated at least one LR-M fea-
ture. Lee et al.49 reported that at least one LR-M feature was 
observed in 94% (31/33) of cHCC-CCAs and 51% (34/66) of 
HCCs. It was suggested that cHCC-CCA could be diagnosed 
with a sensitivity of 55% and specificity of 94% when the le-
sion exhibits three or more LR-M features. Other recent 
studies reported that 61% of cHCC-CCAs were classified as 
LR-M and 23-36% as LR-5.47,48 When cHCC-CCAs are cate-
Figure 3. A 50-year-old female showing combined hepatocellular-cholangiocarcinoma (chcc-ccA), developed in b viral cirrhosis. A 1.7-cm tumor 
in the liver segment 2 shows low-signal intensity on precontrast T1-weighted image (A), non-peripheral enhancement in the arterial phase (b), 
washout and enhancing capsule on portal phase (c) and 2-minutes delay phase (d) of gadoterate meglumine-enhanced magnetic resonance 
imaging (white arrows). The lesion also shows high signal intensity in T2-weighted image (e) and diffusion-weighted image (f, b=800). Since the 
lesion exhibits three major features of liver imaging and Reporting and data System, it is categorized as hcc (lR-5). On pathologic examination, 
the tumor is composed of two histologic components (g-l), showing large area of hcc (J) and small area of ccA (k) on hematoxylin-eosin (h-e) 
staining. Alcian-blue staining shows mucin, stained as blue color, at ccA (l, red arrows) ([g] gross feature of resected specimen; [h] scanning view 
of h-e stain; [i] map of histological component; [J, k] h-e stain, original magnification, ×100; [l] scanning view of Alcian-blue stain).
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gorized as LR-5, they might lead to inappropriate treatment 
strategies. 
HCC-like or CCA-like (LR-M) imaging features do not al-
ways reflect the dominant histologic component of cHCC-
CCA. HCC-dominant cHCC-CCA might show peripheral ar-
terial enhancement, and CCA-dominant cHCC-CCA might 
exhibit global enhancement.24,50 Interestingly, several recent 
reports have proposed that cHCC-CCAs with HCC-like imag-
ing patterns demonstrate a better prognosis than those with a 
CCA-like imaging pattern. The imaging pattern is a better sur-
rogate than the histologic pattern for predicting outcome after 
hepatic resection.24,48,50,51 The clinical, histological, and radio-
logical characteristics of PLCs are summarized in Table 3.
BIOpsy DIagNOsIs Of chCC-CCa
As only part of the tumor tissue can be sampled by percu-
taneous biopsy, there is an effect of sampling on the diagno-
sis of cHCC-CCA (Fig. 4). For those cases of cHCC-CCA 
composed predominantly of HCC or CCA area, the other 





Chronic hepatitis or cirrhosis, related with 
hepatitis B, hepatitis C, or alcoholic liver 
disease
Chronic hepatitis or cirrhosis; the 
incidence is similar to HCC or 
intermediate between HCC and 
CCA 
Bile duct diseases including 
parasitic fluke, primary sclerosing 
cholangitis, and choledocolithiasis; 
Could be associated with chronic 
hepatitis or cirrhosis in small duct 
type CCA
Serum markers AFP elevation AFP elevation, similar to HCC and 
higher than CCA;
CA19-9 level could be increased




Tumor cells showing hepatocyte like 
features including polygonal shape, 
round vesicular nuclei, and prominent 
nucleoli; 
Various histologic patterns including 
trabecular, pseudoglandular, and 
compact patterns
Unequivocal area of HCC and CCA;
Varying proportion of stem/
progenitor features, showing small 
cells with scant cytoplasm, a high 
nuclear/cytoplasmic ratio, and 
hyperchromatic nuclei
Tumor cells forming tubular glands 
with varying degree of cytologic 
atypia; 
Often have a significant amount of 
dense fibrous stroma
IHC markers IHC markers for hepatocytic 
differentiation: HepPar-1, Arginase-1, 
canalicular expression of pCEA and/or 
CD10, etc
IHC markers both of hepatocytic and 
cholangiocytic differentiation:
Variable expression of IHC markers 
for stem/progenitor cells (K19, 
EpCAM, CD56, KIT, and CD133, etc)
IHC markers for cholangiocytic 




Non-peripheral arterial phase 
enhancement; 
Washout in venous and/or delay phases; 
Enhancing capsule; 
Fat in mass; 
Mosaic appearance
Could show radiologic findings of 
HCC or CCA
Peripheral arterial phase 
enhancement; 
Progressive central enhancement; 
Hepatobiliary phase target 
appearance; 
Surface retraction;  
Bile duct dilatation
LI-RADS category Commonly LR-5 or LR-4 LR-M, LR-5, or LR-4 Commonly LR-M
HCC, Hepatocellular carcinoma; cHCC-CCA, combined hepatocellular-cholangiocarcinoma; CCA, cholangiocarcinoma; AFP, alpha-fetoprotein; 
CEA, carcinoembryonic antigen; IHC, immunohistochemical; LI-RADS, Liver Imaging and Reporting and Data System; LR-M, Liver Imaging 
Reporting and Data System M.
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components might not be included in the biopsied tissue, 
making a sampling error leading to an incorrect diagnosis. 
Gigante et al.52 studied 21 cases of biopsy-resection-matched 
cHCC-CCAs. They found that only 48% (10/21) of cHCC-
CCAs were diagnosed correctly by biopsy. The remaining 
52% (11/21) cHCC-CCAs were misdiagnosed as CCAs or 
HCCs. The expression of IHC markers often show similar 
patterns in biopsied and resected tumor tissues, which may 
help in the diagnosis of cHCC-CCA in biopsy specimens.52,53 
Besides, there is little knowledge on whether radiologic imag-
ing can distinguish various histologic components. Even if 
possible, small tumor areas with different histologic compo-
nents might be difficult to obtain by image-guided biopsy.
CONClUsION aND fUTURe peRspeC-
TIVes
There are still many unknowns in the pathogenesis, histo-
pathology, and genetics of cHCC-CCAs. Recent research has 
highlighted that cHCC-CCAs are more heterogeneous than 
previously expected. The recently updated consensus termi-
nology and the WHO 2019 classification for cHCC-CCAs, 
Figure 4. A 67-year-old male with combined hepatocellular-cholangiocarcinoma (chcc-ccA), developed in c viral cirrhosis with matched 
biopsied and resected specimen. The gadoxetate-enhanced magnetic resonance imaging shows approximately 2.4 cm mass lesion with low-
signal intensity in precontrast T1-weighted image (A), peripheral enhancement in the arterial phase (b), absence of washout in portal phase (c) 
and decreased hepatobiliary uptake in hepatobiliary phase (d), high signal intensity in T2-weighted image (e), and targetoid restriction in 
diffusion-weighted image (f, b=800). The patient has past history of distal common bile duct cancer (26 years ago), and recently diagnosed 
squamous cell carcinoma of oral cavity. To determine whether the lesion is metastasis, percutaneous liver biopsy was performed. The biopsy 
specimen shows adenocarcinoma without other component (g, h). The patient underwent hepatic resection and the tumor reveals chcc-ccA (i, 
J). There is large area of cholangiocarcinoma (approximately 90%) and small area of hepatocellular carcinoma (approximately 10%) with 
transitional differentiation zones between them ([g] hematoxylin-eosin stain [h-e], original magnification, ×100; [h, i] scanning view of h-e stain; 
[J] h-e stain, original magnification, ×40).
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enabling clear and informative descriptions, are expected to 
facilitate multi-center and multi-national research. 
Most cHCC-CCAs arise in the background of chronic 
hepatitis or cirrhosis; therefore, the primary differential im-
aging diagnosis is HCC. cHCC-CCAs showing typical imag-
ing findings of HCC can be misdiagnosed and subjected to 
inappropriate treatment if other clinical findings are not ade-
quately considered. Using only imaging modalities may lead 
to misdiagnosis of cHCC-CCAs with minor histologic com-
ponents. Nevertheless, several reports have demonstrated the 
prognostic significance of imaging findings of cHCC-CCA, 
suggesting that imaging is a useful clinical decision-making 
tool at the preoperative stage.
As most cHCC-CCAs show at least one LR-M (CCA-like) 
imaging feature in addition to those of HCC, it is often sub-
jected to biopsy for diagnosis. However, there may be sam-
pling error, as only a part of the tumor tissue is sampled dur-
ing biopsy. For appropriate pathologic diagnosis of cHCC-
CCAs, surgical specimens including all tumor components, 
even minor ones, are preferred. It is necessary to develop an 
optimal diagnostic algorithm using clinical, radiologic, and 
histopathologic biopsy information. Several retrospective 
single-center studies attempted to optimize radiological cri-
teria utilizing LR-M features, combining radiologic and sero-
logic findings, or combining radiological findings and biopsy 
results.38,49,52 Because these criteria do not have sufficient di-
agnostic accuracy for cHCC-CCAs, further optimization and 
external validation are required. Furthermore, the discovery 
of non-invasive molecular surrogates, such as novel serum 
markers, could be a solution for overcoming various obsta-
cles in the diagnosis of cHCC-CCA.
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